213 related articles for article (PubMed ID: 7896946)
1. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis.
Heickendorff L; Zachariae H; Bjerring P; Halkier-Sørensen L; Søndergaard K
J Am Acad Dermatol; 1995 Apr; 32(4):584-8. PubMed ID: 7896946
[TBL] [Abstract][Full Text] [Related]
2. Increased levels of type I and III collagen and hyaluronan in scleroderma skin.
Søndergaard K; Heickendorff L; Risteli L; Risteli J; Zachariae H; Stengaard-Pedersen K; Deleuran B
Br J Dermatol; 1997 Jan; 136(1):47-53. PubMed ID: 9039294
[TBL] [Abstract][Full Text] [Related]
3. Photopheresis in systemic sclerosis: clinical and serological studies using markers of collagen metabolism.
Zachariae H; Bjerring P; Heickendorff L; Møller B; Wallevik K; Angelo H
Acta Derm Venereol; 1993 Oct; 73(5):356-61. PubMed ID: 7904402
[TBL] [Abstract][Full Text] [Related]
4. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. A follow-up--investigations in subclasses and during therapy.
Heickendorff L; Parvez A; Bjerring P; Halkier-Sørensen L; Zachariae H
Acta Derm Venereol; 1991; 71(3):185-8. PubMed ID: 1678217
[TBL] [Abstract][Full Text] [Related]
5. Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement.
Scheja A; Wildt M; Wollheim FA; Akesson A; Saxne T
Rheumatology (Oxford); 2000 Oct; 39(10):1110-3. PubMed ID: 11035131
[TBL] [Abstract][Full Text] [Related]
6. Serum markers of type I collagen synthesis and degradation in amyotrophic lateral sclerosis.
Ono S; Imai T; Shimizu N; Nakayama M; Yamano T; Tsumura M
Eur Neurol; 2000; 44(1):49-56. PubMed ID: 10894996
[TBL] [Abstract][Full Text] [Related]
7. Serum markers of collagen synthesis and degradation in skin diseases. Altered levels in diseases with systemic manifestation and during systemic glucocorticoid treatment.
Autio P; Risteli J; Kiistala U; Risteli L; Karvonen J; Oikarinen A
Arch Dermatol Res; 1993; 285(6):322-7. PubMed ID: 8215582
[TBL] [Abstract][Full Text] [Related]
8. [Studies of type I collagen related substances as bone metastatic markers of prostate carcinoma with special regard to serum carboxyterminal propeptide of type. I. Procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and Urinary deoxypyridinoline levels].
Imai T; Honda M; Maeda S; Hosoya Y; Arai T; Sumi S; Umeda H; Yano M; Koga F; Arai K; Yoshida K
Nihon Hinyokika Gakkai Zasshi; 1998 Apr; 89(4):484-91. PubMed ID: 9597867
[TBL] [Abstract][Full Text] [Related]
9. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG).
Abildgaard N; Bentzen SM; Nielsen JL; Heickendorff L
Br J Haematol; 1997 Jan; 96(1):103-10. PubMed ID: 9012695
[TBL] [Abstract][Full Text] [Related]
10. Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis.
Lammi L; Kinnula V; Lähde S; Risteli J; Pääkkö P; Lakari E; Ryhänen L
Eur Respir J; 1997 Dec; 10(12):2725-30. PubMed ID: 9493651
[TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
Akimoto S; Akakura K; Shimazaki J
Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
[TBL] [Abstract][Full Text] [Related]
12. Perinatal collagen turnover markers in intrauterine growth restriction.
Gourgiotis D; Briana DD; Georgiadis A; Boutsikou M; Baka S; Marmarinos A; Hassiakos D; Malamitsi-Puchner A
J Matern Fetal Neonatal Med; 2012 Sep; 25(9):1719-22. PubMed ID: 22339296
[TBL] [Abstract][Full Text] [Related]
13. Carboxyterminal type I procollagen peptide concentrations in systemic sclerosis: higher levels in early diffuse disease.
Scheja A; Hellmer G; Wollheim FA; Akesson A
Br J Rheumatol; 1993 Jan; 32(1):59-62. PubMed ID: 8422562
[TBL] [Abstract][Full Text] [Related]
14. Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy.
Kjeldsen J; Schaffalitzky de Muckadell OB; Junker P
Gut; 1995 Dec; 37(6):805-10. PubMed ID: 8537052
[TBL] [Abstract][Full Text] [Related]
15. Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen.
Oikarinen A; Autio P; Vuori J; Väänänen K; Risteli L; Kiistala U; Risteli J
Br J Dermatol; 1992 Feb; 126(2):172-8. PubMed ID: 1536783
[TBL] [Abstract][Full Text] [Related]
16. Dupuytren's disease in type I diabetic subjects: investigation of biochemical markers of type III and I collagen.
Arkkila PE; Koskinen PJ; Kantola IM; Rönnemaa T; Seppänen E; Viikari JS
Clin Exp Rheumatol; 2000; 18(2):215-9. PubMed ID: 10812494
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis.
Scheja A; Akesson A; Hørslev-Petersen K
Scand J Rheumatol; 1992; 21(1):5-9. PubMed ID: 1570489
[TBL] [Abstract][Full Text] [Related]
18. Serum aminoterminal propeptide of type III procollagen in progressive systemic sclerosis and localized scleroderma.
Zachariae H; Halkier-Sørensen L; Heickendorff L
Acta Derm Venereol; 1989; 69(1):66-70. PubMed ID: 2563612
[TBL] [Abstract][Full Text] [Related]
19. Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis.
Hakala M; Aman S; Luukkainen R; Risteli L; Kauppi M; Nieminen P; Risteli J
Ann Rheum Dis; 1995 Nov; 54(11):886-90. PubMed ID: 7492237
[TBL] [Abstract][Full Text] [Related]
20. Serum concentrations of aminoterminal propeptide of type III procollagen and propeptide of human type I procollagen in systemic lupus erythematosus.
Villa-Manzano AI; Gamez-Nava JI; Salazar-Paramo M; Valera-Gonzalez IC; Garcia-Gonzalez A; Garcia-Gonzalez G; Morales-Romero J; Lopez-Olivo A; Galvan-Ramirez LM; Ruiz-Ruvalcaba R; Cardona-Muñoz EG; Gonzalez-Lopez L
Rheumatol Int; 2006 Jun; 26(8):712-6. PubMed ID: 16231121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
